Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment [9]

Chest

Volumn 127, Issue 6, 2005, Pages 2288-2289

  Spinler, Sarah A ^a,c   Dobesh, Paul ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEMOGLOBIN; HEPARIN; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; ECCHYMOSIS; HEART CATHETERIZATION; HEART INFARCTION; HEMATOMA; HUMAN; ISCHEMIA; KIDNEY DISEASE; LETTER; OBESITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; UNSTABLE ANGINA PECTORIS; ACUTE DISEASE; BIOAVAILABILITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; NOTE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; ANGINA, UNSTABLE; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 21844468772     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.6.2288     Document Type: Article

References (16)

1. Macie C, Forbes L, Foster GA, et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004; 125:1616-1621
2. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable anginal results of TIMI 11A. J Am Coll Cardiol 1997; 29:1474-1482
3. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110:392-398
4. Becker RC, Spencer FA, Bruno R, et al. Excess body weight does not adversely influence either bioavailability or anticoagulant activity of enoxaparin administered subcutaneously in acute coronary syndromes [abstract]. Circulation 2000; 102(Suppl 2):II427-II428
5. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72:308-318
6. Spinler SA, Inverso SM, Cohen M, et al. ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41
7. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347:561-568
8. Nightingale SL. From the Food and Drug Administration. JAMA 1993; 270:1672
9. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary heart disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-68
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100:1593-1601
11. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447-452
12. Ferguson JJ, Califf RM, Antman EM, et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54
13. Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003; 146:304-310
14. Klein W, Kraxner W, Hodl R, et al. GRACE Investigators. Patterns of use of heparins in ACS: correlates and hospital outcomes; the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 2003; 90:519-527
15. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823
16. Cohen M, Mahaffey KW, White HD, et al. Enoxaparin 0.3 mg/kg intravenous supplement for patients transitioning to percutaneous coronary intervention: Results from SYNERGY [abstract]. Am J Cardiol 2004; 85:38E-39E